Alkylating agents
Chemoradiotherapy + Stem Cell Transplant for Blood Cancers
This trial is giving chemotherapy drugs and HT before a donor stem cell transplant to see if it helps stop the growth of cancer cells and also helps stop the patient's immune system from rejecting the donor's stem cells.
JAK Inhibitor
Ruxolitinib + Chemotherapy for Leukemia
This trial is testing a new cancer drug, ruxolitinib, in combination with standard chemotherapy to treat B-cell acute lymphoblastic leukemia. The study will first find the best dose of ruxolitinib to use with chemotherapy, then test how well the combination works at that dose.
Cell Therapy
Stem Cell Transplant for Blood Cancers
This trial is testing a new stem cell transplantation method for people with blood cancers. The new method uses a machine to remove certain cells from the donor stem cells, and it also removes a different type of cell from the patient before transplant. The trial will measure how well the transplant works and how long the patient survives without the cancer coming back.
Popular Filters
Trials for Acute Myeloid Leukemia Patients
Bruton's Tyrosine Kinase (BTK) Inhibitor
PCI-32765 for Chronic Lymphocytic Leukemia
This trial is testing a new cancer treatment drug, PCI-32765, to see if it can treat chronic lymphocytic leukemia and small lymphocytic lymphoma in elderly people and people with 17p deletion.
CAR T-cell Therapy
Kappa CD28 T Cells for Leukemia
This trial is testing a new treatment for patients with a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. The treatment is a gene transfer research study using special immune cells. The study is testing whether combining two different ways of fighting disease, antibodies and T cells, will be more effective than using either method alone.
Alkylating agents
IMRT + Chemotherapy + Stem Cell Transplant for Leukemia
This trial is giving IMRT with chemotherapy to patients with relapsed or refractory ALL or AML before a donor stem cell transplant. The aim is to find out the side effects of this treatment and the best dose of IMRT to give, as well as how well the IMRT and chemotherapy work in treating patients.
Trials for Acute Lymphoblastic Leukemia Patients
Bruton's Tyrosine Kinase (BTK) Inhibitor
PCI-32765 for Chronic Lymphocytic Leukemia
This trial is testing a new cancer treatment drug, PCI-32765, to see if it can treat chronic lymphocytic leukemia and small lymphocytic lymphoma in elderly people and people with 17p deletion.
CAR T-cell Therapy
Kappa CD28 T Cells for Leukemia
This trial is testing a new treatment for patients with a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. The treatment is a gene transfer research study using special immune cells. The study is testing whether combining two different ways of fighting disease, antibodies and T cells, will be more effective than using either method alone.
Trials for CD19 Positive Patients
Stem Cell Transplantation
Stem Cell Transplant for Bone Marrow Failure Syndrome
This trial is for children with a serious disease who are not eligible for other stem cell transplant protocols. The goal is to expand access for patients who lack a fully HLA matched sibling donor.
Phase 3 Trials
Probiotic
Probiotics for Preventing Graft-versus-Host Disease
This trial is testing whether Lactobacillus plantarum, a beneficial bacteria found in foods like yogurt, can prevent a serious gut complication called acute graft versus host disease in young patients receiving stem cell transplants. The bacteria may help by keeping the gut healthy and reducing inflammation. Lactobacillus plantarum has been used in human studies to promote beneficial effects in the immune system, alleviate intestinal disorders, and reduce the risk of cardiovascular disease. The study will compare patients taking Lactobacillus plantarum to those not taking it.
Chemotherapy
New Cancer Treatment for Non-Hodgkin's Lymphoma
This trial is testing a new cancer treatment for children with B-cell NHL. The new treatment is based on the successful LMB-96 regimen. The trial features prospective biologic and late effect studies.
Trials With No Placebo
Bruton's Tyrosine Kinase (BTK) Inhibitor
PCI-32765 for Chronic Lymphocytic Leukemia
This trial is testing a new cancer treatment drug, PCI-32765, to see if it can treat chronic lymphocytic leukemia and small lymphocytic lymphoma in elderly people and people with 17p deletion.
CAR T-cell Therapy
Kappa CD28 T Cells for Leukemia
This trial is testing a new treatment for patients with a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. The treatment is a gene transfer research study using special immune cells. The study is testing whether combining two different ways of fighting disease, antibodies and T cells, will be more effective than using either method alone.
View More Related Trials
Frequently Asked Questions
Introduction to leukemia
What are the top hospitals conducting leukemia research?
When it comes to cutting-edge clinical trials in the battle against leukemia, several hospitals across the United States are leading the way. In Houston, M D Anderson Cancer Center stands out with nine active leukemia trials and an impressive 209 completed trials throughout its history. This renowned institution recorded its first leukemia trial back in 1999 and has since been at the forefront of innovative research. Not far behind is Boston's Dana-Farber Cancer Institute, which also boasts nine ongoing leukemia trials alongside a remarkable record of 184 previously conducted studies dating back to their inaugural trial in 1993.
Meanwhile, Memorial Sloan Kettering Cancer Center in New york City has made significant contributions as well, currently conducting nine active leukemia trials while having accomplished a noteworthy total of 182 previous investigations since initiating their first trial in 1994. Another notable hospital making strides is MD Anderson Cancer Center once again based in Houston; they have eight ongoing leukemia clinical trials under their belt while having conducted a commendable number154 prior experiments since undertaking their initial investigation into this condition back in 1996.
In addition to these institutions, Massachusetts General Hospital Cancer Center located in Boston plays an important role too, with seven current leukemia clinical trials and contributing towards advancement through their fifty-seven previously held investigations; theirs can be traced back twenty-four years ago when they began recording such cases way back until 1997.
These hospitals represent not only hope for those affected by leukemia but also exemplify the relentless dedication of medical professionals nationwide who strive to conquer this disease. The combined efforts of these top-tier facilities push us closer toward breakthroughs that will ultimately transform the lives of countless patients battling this formidable illness globally
Which are the best cities for leukemia clinical trials?
When it comes to leukemia clinical trials, several cities are at the forefront of research and development. Boston, Massachusetts leads with 41 active trials focused on treatment options like cytarabine and AZD6738. Houston, Texas closely follows with 35 ongoing studies exploring treatments such as Dasatinib and JAKi Naïve Combination Arm. New york, New York also stands out with 31 active trials investigating treatment options including Dasatinib and JAKi Naïve Combination Arm. In addition, Chicago, Illinois contributes significantly to leukemia research with 27 active trials studying drugs like Dasatinib and Daunorubicin Hydrochloride. Lastly, Los Angeles, California offers access to 21 active trials examining various treatment approaches for leukemia patients. These cities serve as hotspots for cutting-edge clinical trials that push the boundaries of leukemia care and bring hope to those affected by this disease.
Which are the top treatments for leukemia being explored in clinical trials?
Leukemia research is making significant strides, with several promising treatments currently being explored in clinical trials. Among the top contenders are dasatinib, a drug that has shown promise in three active trials and boasts an impressive 100 all-time leukemia trials since its introduction in 2001. Another noteworthy contender is ruxolitinib, which is currently being tested in two ongoing trials and has accumulated 29 all-time leukemia trials since its first listing in 2010. Additionally, venetoclax shows great potential with two active trials and an extensive track record of 220 all-time leukemia trials dating back to its initial listing in 2007. These innovative therapies offer hope for improved outcomes for patients battling this challenging disease as researchers strive to uncover new treatment options through rigorous clinical exploration.
What are the most recent clinical trials for leukemia?
Exciting advancements are underway in the field of leukemia research, with recent clinical trials offering hope for improved treatments. One such trial is investigating Leukemia CNS1 or 2, a phase 2 study aimed at evaluating its effectiveness against leukemia. Additionally, GDX012 has shown promise in dose escalation studies as a potential treatment option for leukemia patients. CB-103 and pirtobrutinib are also being investigated in separate phase 2 trials to assess their efficacy and safety profiles. Finally, an innovative approach involving anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) is undergoing both Phase 1 and Phase 2 testing as a potential therapy for leukemia. These ongoing trials hold immense potential to improve outcomes and quality of life for individuals battling this challenging disease.
What leukemia clinical trials were recently completed?
In a series of recent advancements in the field of leukemia research, several clinical trials have been successfully completed. Noteworthy among these achievements are the completion of trials for Lemzoparlimab sponsored by AbbVie in June 2021 and Azacitidine sponsored by Pfizer in May 2021. Furthermore, a trial for mRNA-1273 conducted under the National Cancer Institute's sponsorship was finalized in April 2021. These significant milestones demonstrate the ongoing dedication to finding effective treatments for leukemia and offer hope to those affected by this challenging disease.